BRPI0414698A - combinação de um inibidor receptor de vegf com um agente quimioterapêutico - Google Patents
combinação de um inibidor receptor de vegf com um agente quimioterapêuticoInfo
- Publication number
- BRPI0414698A BRPI0414698A BRPI0414698-0A BRPI0414698A BRPI0414698A BR PI0414698 A BRPI0414698 A BR PI0414698A BR PI0414698 A BRPI0414698 A BR PI0414698A BR PI0414698 A BRPI0414698 A BR PI0414698A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- inhibitors
- compound
- vegf
- topoisomerase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 108091008605 VEGF receptors Proteins 0.000 title abstract 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 abstract 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 abstract 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 102400000967 Bradykinin Human genes 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 206010066476 Haematological malignancy Diseases 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 229940122588 Heparanase inhibitor Drugs 0.000 abstract 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 abstract 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 abstract 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 abstract 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 abstract 1
- 229940123582 Telomerase inhibitor Drugs 0.000 abstract 1
- 108091033399 Telomestatin Proteins 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 abstract 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000000964 angiostatic effect Effects 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 230000009949 anti-apoptotic pathway Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 230000000719 anti-leukaemic effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229930195545 bengamide Natural products 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000008512 biological response Effects 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229960001442 gonadorelin Drugs 0.000 abstract 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 238000002428 photodynamic therapy Methods 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 230000008569 process Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 239000003277 telomerase inhibitor Substances 0.000 abstract 1
- YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 230000034512 ubiquitination Effects 0.000 abstract 1
- 238000010798 ubiquitination Methods 0.000 abstract 1
- 239000002525 vasculotropin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50525003P | 2003-09-23 | 2003-09-23 | |
| PCT/EP2004/010686 WO2005027972A2 (en) | 2003-09-23 | 2004-09-23 | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414698A true BRPI0414698A (pt) | 2006-11-28 |
Family
ID=34375569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414698-0A BRPI0414698A (pt) | 2003-09-23 | 2004-09-23 | combinação de um inibidor receptor de vegf com um agente quimioterapêutico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085902A1 (https=) |
| EP (1) | EP1682181A2 (https=) |
| JP (1) | JP2007505938A (https=) |
| KR (1) | KR20060097000A (https=) |
| CN (1) | CN1856327A (https=) |
| AU (1) | AU2004273615B2 (https=) |
| BR (1) | BRPI0414698A (https=) |
| CA (1) | CA2537991A1 (https=) |
| CO (1) | CO5680459A2 (https=) |
| CR (1) | CR8283A (https=) |
| EA (1) | EA200600495A1 (https=) |
| EC (1) | ECSP066437A (https=) |
| IL (1) | IL174214A0 (https=) |
| MX (1) | MXPA06003163A (https=) |
| NO (1) | NO20061777L (https=) |
| WO (1) | WO2005027972A2 (https=) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| AU2004212633B2 (en) * | 2003-02-21 | 2010-12-09 | ResMed Pty Ltd | Nasal assembly |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| ES2537631T3 (es) | 2004-05-27 | 2015-06-10 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| JP2008514576A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法 |
| EP1817295B1 (en) | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| ATE482693T1 (de) * | 2005-03-07 | 2010-10-15 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| US20080219977A1 (en) * | 2005-07-27 | 2008-09-11 | Isaiah Josh Fidler | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP1942882A2 (en) * | 2005-10-24 | 2008-07-16 | Novartis AG | Combination of histone deacetylase inhibitors and radiation |
| AU2006309551B2 (en) * | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| CN100441222C (zh) * | 2005-12-09 | 2008-12-10 | 中国科学院广州生物医药与健康研究院 | 化合物ps-341在制备治疗急性髓性白血病药物中的应用 |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| ME00529B (me) | 2006-06-12 | 2011-10-10 | Novartis Ag | Polimorfi n-hidroksi-3-[4-[[[2-(-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| EP2030615A3 (en) | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| JP2012517434A (ja) * | 2009-02-06 | 2012-08-02 | ザ ジェネラル ホスピタル コーポレイション | 血管病変を治療する方法 |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| EP2484359B1 (en) * | 2009-09-30 | 2018-07-25 | Shiseido Company, Ltd. | Heparanase activity inhibitor |
| ES2468827T3 (es) | 2010-01-14 | 2014-06-17 | Sanwa Kagaku Kenkyusho Co., Ltd | Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| EP2671589A4 (en) | 2011-02-02 | 2014-11-19 | Public Univ Corp Nagoya City Univ | MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| JP2015536964A (ja) * | 2012-11-08 | 2015-12-24 | ノバルティス アーゲー | Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| WO2016010886A1 (en) * | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| BR102014023144B1 (pt) * | 2014-09-18 | 2020-12-15 | Universidade De São Paulo - Usp | peptídeos sintéticos ligantes de receptores de vegf e seus usos |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| WO2025160930A1 (zh) * | 2024-02-02 | 2025-08-07 | 基亚生物科技股份有限公司 | 母帕司汀(Muparfostat)治疗胰腺癌的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002066479A1 (en) * | 2001-02-23 | 2002-08-29 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindole derivatives |
| PL367349A1 (en) * | 2001-09-12 | 2005-02-21 | Novartis Ag | Use of 4-pyridylmethylphthalazines for cancer treatment |
| US20050043409A1 (en) * | 2001-10-25 | 2005-02-24 | Chen Ying-Nan Pan | Combinations comprising a selective cyclooxygenase-2 inhibitor |
| CA2468996A1 (en) * | 2001-12-03 | 2003-06-12 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
-
2004
- 2004-09-23 US US10/573,163 patent/US20080085902A1/en not_active Abandoned
- 2004-09-23 MX MXPA06003163A patent/MXPA06003163A/es not_active Application Discontinuation
- 2004-09-23 CN CNA2004800275441A patent/CN1856327A/zh active Pending
- 2004-09-23 AU AU2004273615A patent/AU2004273615B2/en not_active Ceased
- 2004-09-23 WO PCT/EP2004/010686 patent/WO2005027972A2/en not_active Ceased
- 2004-09-23 BR BRPI0414698-0A patent/BRPI0414698A/pt not_active IP Right Cessation
- 2004-09-23 EA EA200600495A patent/EA200600495A1/ru unknown
- 2004-09-23 CA CA002537991A patent/CA2537991A1/en not_active Abandoned
- 2004-09-23 JP JP2006527348A patent/JP2007505938A/ja active Pending
- 2004-09-23 EP EP04765542A patent/EP1682181A2/en not_active Withdrawn
- 2004-09-23 KR KR1020067005644A patent/KR20060097000A/ko not_active Withdrawn
-
2006
- 2006-03-09 IL IL174214A patent/IL174214A0/en unknown
- 2006-03-14 CR CR8283A patent/CR8283A/es not_active Application Discontinuation
- 2006-03-17 EC EC2006006437A patent/ECSP066437A/es unknown
- 2006-03-30 CO CO06031465A patent/CO5680459A2/es not_active Application Discontinuation
- 2006-04-21 NO NO20061777A patent/NO20061777L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5680459A2 (es) | 2006-09-29 |
| EP1682181A2 (en) | 2006-07-26 |
| WO2005027972A2 (en) | 2005-03-31 |
| CA2537991A1 (en) | 2005-03-31 |
| IL174214A0 (en) | 2006-08-01 |
| AU2004273615A1 (en) | 2005-03-31 |
| AU2004273615B2 (en) | 2009-01-15 |
| CN1856327A (zh) | 2006-11-01 |
| WO2005027972A3 (en) | 2005-11-03 |
| KR20060097000A (ko) | 2006-09-13 |
| MXPA06003163A (es) | 2006-06-05 |
| JP2007505938A (ja) | 2007-03-15 |
| EA200600495A1 (ru) | 2006-10-27 |
| CR8283A (es) | 2006-10-10 |
| ECSP066437A (es) | 2006-09-18 |
| US20080085902A1 (en) | 2008-04-10 |
| NO20061777L (no) | 2006-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414698A (pt) | combinação de um inibidor receptor de vegf com um agente quimioterapêutico | |
| JP2007505938A5 (https=) | ||
| Hossmann et al. | Effects of electromagnetic radiation of mobile phones on the central nervous system | |
| Peters et al. | Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390) | |
| BRPI0417158A (pt) | composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença | |
| ZA200704701B (en) | Combination of therapeutic agents for treating cancer | |
| AR065335A1 (es) | Combinaciones de agentes terapeuticos para el tratamiento de cancer | |
| RU2003127391A (ru) | Лечение рака | |
| RU2007141994A (ru) | Применение антител к cd25 в иммунотерапии | |
| BR0014320A (pt) | Composições de substâncias terapêuticas solúveis em tocol | |
| BR9813256A (pt) | Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente | |
| NO20034204D0 (no) | Farmasöytiske kombinasjoner til behandling av kreft | |
| Boadle-Biber et al. | Tryptophan hydroxylase: increase in activity by electrical stimulation of serotonergic neurons | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BRPI0517075A (pt) | uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer | |
| Sperlágh et al. | Is the neuronal ATP release from guinea-pig vas deferens subject to α2-adrenoceptor-mediated modulation? | |
| Altar et al. | Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release | |
| TR200500108T2 (tr) | Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz Kullanımı | |
| ATE253575T1 (de) | N-benzensulfonyl-l-prolin derivate und deren verwendung als bradykinin antagonisten | |
| Thakur et al. | Targeting extracellular matrix remodeling sensitizes glioblastoma to ionizing radiation | |
| GB0012526D0 (en) | Triterpenoid derivatives | |
| SI1604211T1 (sl) | Indentifikacija terapevtskih spojin | |
| Papadopoulou et al. | Radiosensitization and Hypoxic Cell Toxicity of NLA‐1 and NLA‐2, Two New Bioreductive Compounds | |
| Watts et al. | Radiosensitization by misonidazole, pimonidazole and azomycin and intracellular uptake in human tumour cell lines | |
| Fowler et al. | The effect of selective noradrenergic lesions upon the stimulation by noradrenaline of inositol phospholipid breakdown in rat hippocampal miniprisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |